Drug intelligence / Profile preview

C-10276 + CTP-518

Development stage: Unknown
Lead developer: Concert Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**C-10276 + CTP-518** is a combination of two investigational agents, both isotopologs of the HIV-1 protease inhibitor atazanavir. C-10276 is an atazanavir isotopolog, and CTP-518 is a stable, deuterium-containing isotopolog of atazanavir developed to enhance half-life and reduce hepatic metabolism. The combination is studied for antiretroviral therapy, co-administered to evaluate pharmacokinetics, safety, and tolerability in healthy volunteers. Both were tested as single agents and in combination with each other and with Reyataz (atazanavir) in clinical trials.

Targets

PR (Progesterone receptor)

Beyond the preview

Go deeper on C-10276 + CTP-518.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-10276 + CTP-518.

Explore the full profile